- Uses
heat and light energy to provide non-invasive and pain-free skin care
- InterceptCS™
provides cold sore prevention with controlled topical heat
- TherOZap™
relieves symptoms caused by insect and marine life bites and stings, holds
potential for inhibiting mosquito-borne viruses
- A
third product is in development to treat joint pain through the
combination of cannabis and thermal technology
Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a
progressive medical device technology company focused on serving the $21
billion cosmeceutical industry by providing products, devices and treatments
that address dermatological needs. The company believes that clear and healthy
skin should not be a privilege for those who can afford costly procedures and
treatments, but rather a possibility that is accessible for all.
Heat and light energy are used by ThermaBright to provide
non-invasive and pain-free skin care. This proprietary technology has received
Class II medical device status from the U.S. Food and Drug Administration.
Patent and trademark protection have also been initiated for products developed
to incorporate medicinal cannabis into the use of the company’s thermal therapy
tech.
InterceptCS is ThermaBright’s cold sore prevention device*.
This device treats cold sores at their earliest appearance through the
application of topical thermal technology with no risk of burning the skin.
Used at the first sign of a cold sore, InterceptCS can prevent further symptoms
from developing by killing cells that have been infected by the herpes simplex
Type 1 virus.
The market potential for InterceptCS is high, with a
reported 20-40 percent of the Canadian and United States population
experiencing recurrent cold sore outbreaks. No prescription to use this device
is required, making it more accessible to a larger market. Plans are in place
to bring various models to market beyond the current single-use activator,
further elevating the value for the customer.
Another of ThermaBright’s revolutionary products is
TherOZap. This device uses thermal therapy as a second line of defense against
insect bites. The device is used to relieve the pain, itch and swelling that
can result from more than 20,000 types of insect and marine life bites and
stings. These includes bees, wasps, hornets, mosquitos, black flies and
jellyfish. Plans are in place to test the technology’s effectiveness in
inhibiting mosquito-borne diseases such as the Zika and Dengue viruses.
A third product is in the works for a new pain relief
device. This novel device is for the relief of back, knee or other joint pain.
It combines the company’s thermal therapy tech with medical grade cannabis or
cannabidiol (CBD) used as a cream or gel.
In preparation for this unique device, ThermaBright is in
the process of creating a wholly owned subsidiary, according to a recent press
release (http://ibn.fm/5ySjg).
The company has indicated that an acquisition will be sought to further the
development of this new product. The cannabis related device acquisitions,
along with any products created, will be held in this new subsidiary.
For more information, visit the company’s website at www.ThermaBright.com
- Based
on double blind placebo study the InterceptCS™ is approved for the claim
“For prevention of cold sores when used within 3 hours of the onset of the
prodrome.” by Health Canada. The InterceptCS™ is not approved by the
United States FDA for any claim of clinical indication, clinical efficacy,
and/or cure or prevention of disease.
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment